Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects Stefano Rizza, Marina Cardellini, Ottavia Porzio, Chiara Pecchioli, Alessia Savo, Iris Cardolini, Nicoletta Senese, Davide Lauro, Paolo Sbraccia, Renato Lauro, Massimo Federici Atherosclerosis Volume 215, Issue 1, Pages 180-183 (March 2011) DOI: 10.1016/j.atherosclerosis.2010.12.021 Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions
Fig. 1 Effect of pioglitazone on FMD in CAD/IGT patients. CAD/IGT patients were treated with pioglitazone (n=13) or placebo (n=12) for 12 weeks. Analysis of brachial artery flow-mediated-dilation (FMD) was performed before and after treatment. Atherosclerosis 2011 215, 180-183DOI: (10.1016/j.atherosclerosis.2010.12.021) Copyright © 2011 Elsevier Ireland Ltd Terms and Conditions